The stock is listed on the Nasdaq Global Market

Davis Polk advised the book-running manager and representative of the several underwriters in connection with an SEC-registered follow-on offering by NeuroPace, Inc. of 7,475,000 shares of common stock at $10.00 per share, which included 975,000 shares of common stock from the full exercise of the underwriters’ option to purchase additional shares, for total gross proceeds of $74.75 million. NeuroPace’s common stock is listed on the Nasdaq Global Market under the symbol “NPCE.”

Based in Mountain View, California, NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source.

The Davis Polk corporate team comprised partner Alan F. Denenberg and associates Savannah J. Dowling and Robb Dehney. Partner David R. Bauer and associates Jordan Khorshad and Nazli Ungan provided intellectual property advice. Partner Patrick E. Sigmon and associate David J. Beer provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.

 

Copy link to share post